medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 3

<< Back Next >>

Ann Hepatol 2018; 17 (3)

HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats

Zheng Yong-Ping, Zhong Xian-Yang, Huang Yu-Shu, Zheng Can-Bin

Language: English
References: 35
Page: 511-518
PDF size: 486.74 Kb.


ABSTRACT

Introduction and aim. Hepatitis C virus core-binding protein 6 (HCBP6) was previously found to be an hepatitis C virus corebinding protein, its biological function remains unclear. Our research aims to investigate the role of HCBP6 in the development of hepatic steatosis induced by high-fat diet and carbon tetrachloride (CCL4) in rats. Material and methods. Eighteen Wistar rats were randomly allocated into 3 groups: control group, model group 1, and model group 2. The control group was treated with a standard diet for 5 weeks. Model groups were treated with high-fat diet and CCL4 injection twice a week for 3 weeks in Group 1 and 5 weeks in Group 2, respectively. After the intervention, hepatic steatosis was observed by histological staining with hematoxylin and eosin (H&E) and Oil Red O staining. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), and triglycerides (TGs) were measured. The TG content in liver homogenates was evaluated. Expressions of HCBP6 and SREBP-1c were determined by immunofluorescence, quantitative real-time PCR, and Western blot analysis. Results. Hepatic steatosis was successfully induced in model groups. ALT, AST, TC, and TGs elevated in model groups compared with those in control group (P ‹ 0.05). Hepatic steatosis induced by high-fat diet and CCL4 resulted in low expression of HCBP6 and high expression of SREBP-1c in the liver of rats (P ‹ 0.05). Conclusion. HCBP6 is involved in the development of high-fat diet- and CCL4-induced hepatic steatosis and related negatively with SREBP-1c.


REFERENCES

  1. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: 194-8.

  2. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44: 589-95.

  3. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.

  4. Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 2011; 22: 353-63.

  5. Siri P, Candela N, Zhang YL, Ko C, Eusufzai S, Ginsberg HN, Huang LS. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J Biol Chem 2001; 276: 46064-72.

  6. Li K, Wang L, Cheng J, Zhang L, Duan H, LuY, Yang J, et al. Screening and cloning gene of hepatocyte protein interacting with hepatitis C virus core protein. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2002; 16: 351-3.

  7. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-5.

  8. Gao LL, Li M, Wang Q, Liu SA, Zhang JQ, Cheng J. HCBP6 Modulates Triglyceride Homeostasis in Hepatocytes Via the SREBP1c/FASN Pathway. J Cellular Biochem 2015; 116: 2375-84.

  9. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-40.

  10. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPAR gamma. Biochem Biophys Res Commun 2007; 355: 883-8.

  11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.

  12. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.

  13. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-90.

  14. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.

  15. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012; 30: 158-62.

  16. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; 28: 68-76.

  17. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-89.

  18. Koo SH. Nonalcoholic fatty liver disease: Molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 2013; 19: 210-5.

  19. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.

  20. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007; 282: 743-51.

  21. Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H, Onishi Y, Anai M, et al. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 2003; 52: 2905-13.

  22. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest 2008; 118: 829- 38.

  23. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140: 809-17.

  24. Liu M, Liu Y, Cheng J, Zhang SL, Wang L, Shao Q, Zhang J, et al. Transactivating effect of hepatitis C virus core protein: a suppression subtractive hybridization study. World J Gastroenterol 2004; 10: 1746-9.

  25. Yang Z, Liu Z, Cheng J, Wang JJ, Hong Y, Zhang S. Up-regulating effect of human hepatitis C virus core protein-binding protein 6 on NACA promoter. World Chin J Digestol 2003; 11: 959-62.

  26. Wang L, Cheng J, Li K, Hong Y. Identification and evaluation promoter sequence and the transcription activation of Hcbp6 interaction with core protein of hepatitis C virus. Zhonghua Gan Zang Bing Za Zhi 2006; 14: 81-5.

  27. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46.

  28. Shimano H. Sterol regulatory element-binding proteins (SREBPs): Transcriptional regulators of lipid synthetic genes. Prog Lipid Res 2001; 40: 439-52.

  29. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99: 838-45.

  30. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.

  31. Chheda TK, Shivakumar P, Sadasivan SK, Chanderasekharan H, Moolemath Y, Oommen AM, Madanahalli JR, et al. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. BMC Gastroenterol 2014; 14: 89.

  32. Ohta Y, Kongo-Nishimura M, Matsura T, Yamada K, Kitagawa A, Kishikawa T. Melatonin prevents disruption of hepatic reactive oxygen species metabolism in rats treated with carbon tetrachloride. J Pineal Res 2004; 36: 10-7.

  33. Wang CY, Ma FL, Liu JT, Tian JW, Fu FH. Protective effect of salvianic acid A on acute liver injury induced by carbon tetrachloride in rats. Biol Pharm Bull 2007; 30: 44-7.

  34. Breikaa RM, Algandaby MM, El-Demerdash E, Abdel-Naim AB. Biochanin A protects against acute carbon tetrachloride- induced hepatotoxicity in rats. Biosci Biotechnol Biochem 2013; 77: 909-16.

  35. Wahid A, Hamed AN, Eltahir HM, Abouzied MM. Hepatoprotective activity of ethanolic extract of Salix subserrata against CCl4-induced chronic hepatotoxicity in rats. BMC Complement Altern Med 2016; 16: 263.




2020     |     www.medigraphic.com